This poster presents the findings of a global pilot External Quality Assessment (EQA) scheme for FGFR3 testing in urothelial (bladder) cancer.
With bladder cancer ranking as the ninth most common cancer worldwide, accurate detection of FGFR3 variants and fusions is critical for guiding targeted therapy. The study involved 30 accredited laboratories across 15 countries, assessing genotyping accuracy, interpretation, and reporting standards.
Results showed high overall performance but highlighted the need for harmonisation, particularly in fusion nomenclature. This initiative supports improved diagnostic quality and patient care in the era of personalised medicine.
This EQA was supported by Johnson and Johnson.
